S. Lopez

发表

SYD985, a Novel Duocarmycin-Based HER2-Targeting Antibody–Drug Conjugate, Shows Antitumor Activity in Uterine Serous Carcinoma with HER2/Neu Expression

E. Ratner, Serena Wong, D. Silasi, 2016, Molecular Cancer Therapeutics.

In vitro and in vivo activity of sacituzumab govitecan, an antibody-drug conjugate targeting trophoblast cell-surface antigen 2 (Trop-2) in uterine serous carcinoma.

Gloria S. Huang, E. Ratner, D. Silasi, 2019, Gynecologic oncology.

Sacituzumab govitecan, an antibody‐drug conjugate targeting trophoblast cell‐surface antigen 2, shows cytotoxic activity against poorly differentiated endometrial adenocarcinomas in vitro and in vivo

Gloria S. Huang, E. Ratner, D. Silasi, 2019, Molecular oncology.

Preclinical activity of sacituzumab govitecan (IMMU-132) in uterine and ovarian carcinosarcomas

Gloria S. Huang, E. Ratner, R. Angioli, 2020, Oncotarget.

T-DM1, a novel antibody-drug conjugate, is highly effective against uterine and ovarian carcinosarcomas overexpressing HER2

S. Canevari, P. Schwartz, T. Rutherford, 2014, Clinical & Experimental Metastasis.

Cervical carcinomas that overexpress human trophoblast cell-surface marker (Trop-2) are highly sensitive to the antibody-drug conjugate sacituzumab govitecan

Gloria S. Huang, E. Ratner, D. Silasi, 2020, Scientific Reports.

PIK3CA oncogenic mutations represent a major mechanism of resistance to trastuzumab in HER2/neu overexpressing uterine serous carcinomas

E. Ratner, D. Silasi, P. Schwartz, 2015, British Journal of Cancer.

T-DM1, a novel antibody–drug conjugate, is highly effective against primary HER2 overexpressing uterine serous carcinoma in vitro and in vivo

E. Ratner, D. Silasi, P. Schwartz, 2014, Cancer medicine.

Afatinib demonstrates remarkable activity against HER2-amplified uterine serous endometrial cancer in vitro and in vivo

E. Ratner, D. Silasi, T. Rutherford, 2014, British Journal of Cancer.

HER2/neu gene amplification determines the sensitivity of uterine serous carcinoma cell lines to AZD8055, a novel dual mTORC1/2 inhibitor.

P. Schwartz, T. Rutherford, E. Cocco, 2013, Gynecologic oncology.

Neratinib shows efficacy in the treatment of HER2 amplified carcinosarcoma in vitro and in vivo.

E. Ratner, D. Silasi, P. Schwartz, 2015, Gynecologic oncology.

Neratinib shows efficacy in the treatment of HER2/neu amplified uterine serous carcinoma in vitro and in vivo.

P. Schwartz, T. Rutherford, E. Cocco, 2014, Gynecologic oncology.

Oncogenic PIK3CA gene mutations and HER2/neu gene amplifications determine the sensitivity of uterine serous carcinoma cell lines to GDC-0980, a selective inhibitor of Class I PI3 kinase and mTOR kinase (TORC1/2).

D. Silasi, P. Schwartz, T. Rutherford, 2013, American journal of obstetrics and gynecology.

Mutational landscape of uterine and ovarian carcinosarcomas implicates histone genes in epithelial–mesenchymal transition

S. Mane, T. Boggon, Kaya Bilgüvar, 2016, Proceedings of the National Academy of Sciences.

PARP-1 activity (PAR) determines the sensitivity of cervical cancer to olaparib.

Gloria S. Huang, G. Frampton, J. Newberg, 2019, Gynecologic oncology.

Dual HER2/PIK3CA Targeting Overcomes Single-Agent Acquired Resistance in HER2-Amplified Uterine Serous Carcinoma Cell Lines In Vitro and In Vivo

E. Ratner, R. Angioli, D. Silasi, 2015, Molecular Cancer Therapeutics.

Dual HER 2 / PIK 3 CA Targeting Overcomes Single-Agent Acquired Resistance in HER 2-Ampli fi ed Uterine Serous Carcinoma Cell Lines In Vitro and In Vivo

E. Ratner, R. Angioli, D. Silasi, 2015 .

Prevalence and role of HER2 mutations in cancer.

M. Scaltriti, E. Cocco, A. Santin, 2019, Pharmacology & therapeutics.

Mutational landscape of primary, metastatic, and recurrent ovarian cancer reveals c-MYC gains as potential target for BET inhibitors

Gloria S. Huang, R. Lifton, J. Schlessinger, 2018, Proceedings of the National Academy of Sciences.

Novel targeted therapies in ovarian and uterine carcinosarcomas.

A. Santin, G. Menderes, S. Lopez, 2018, Discovery medicine.

Dual CCNE1/PIK3CA targeting is synergistic in CCNE1-amplified/PIK3CA-mutated uterine serous carcinomas in vitro and in vivo

Pei Hui, Jonathan Black, David L Rimm, 2016, British Journal of Cancer.

Polymerase ε (POLE) ultra-mutated tumors induce robust tumor-specific CD4+ T cell responses in endometrial cancer patients.

E. Ratner, D. Silasi, P. Schwartz, 2015, Gynecologic oncology.

PIK3CA oncogenic mutations represent a major mechanism of resistance to trastuzumab in HER2/neu overexpressing uterine serous carcinomas

E. Ratner, D. Silasi, P. Schwartz, 2015, British Journal of Cancer.

Taselisib, a selective inhibitor of PIK3CA, is highly effective on PIK3CA-mutated and HER2/neu amplified uterine serous carcinoma in vitro and in vivo.

R. Angioli, P. Schwartz, T. Rutherford, 2014, Gynecologic oncology.

Dacomitinib (PF-00299804), a second-generation irreversible pan-erbB receptor tyrosine kinase inhibitor, demonstrates remarkable activity against HER2-amplified uterine serous endometrial cancer in vitro

E. Ratner, D. Silasi, P. Schwartz, 2015, Tumor Biology.

Whole-exome sequencing of cervical carcinomas identifies activating ERBB2 and PIK3CA mutations as targets for combination therapy

Gloria S. Huang, L. Alexandrov, T. Boggon, 2019, Proceedings of the National Academy of Sciences.

Solitomab, an epithelial cell adhesion molecule/CD3 bispecific antibody (BiTE), is highly active against primary chemotherapy‐resistant ovarian cancer cell lines in vitro and fresh tumor cells ex vivo

E. Ratner, D. Silasi, T. Rutherford, 2015, Cancer.

Preclinical Activity of Sacituzumab Govitecan, an Antibody-Drug Conjugate Targeting Trophoblast Cell-Surface Antigen 2 (Trop-2) Linked to the Active Metabolite of Irinotecan (SN-38), in Ovarian Cancer

E. Ratner, D. Silasi, P. Schwartz, 2020, Frontiers in Oncology.

Cervical carcinomas that overexpress human trophoblast cell-surface marker (Trop-2) are highly sensitive to the antibody-drug conjugate sacituzumab govitecan

Gloria S. Huang, E. Ratner, D. Silasi, 2020, Scientific Reports.

T-DM1, a novel antibody-drug conjugate, is highly effective against uterine and ovarian carcinosarcomas overexpressing HER2

S. Canevari, P. Schwartz, T. Rutherford, 2014, Clinical & Experimental Metastasis.

PIK3CA oncogenic mutations represent a major mechanism of resistance to trastuzumab in HER2/neu overexpressing uterine serous carcinomas

E. Ratner, D. Silasi, P. Schwartz, 2015, British Journal of Cancer.

Benzene exposure and risk of lymphohaematopoietic cancers in 25 000 offshore oil industry workers

N. Rothman, Q. Lan, E. Ratner, 2015, British Journal of Cancer.

Cervical carcinomas that overexpress human trophoblast cell-surface marker (Trop-2) are highly sensitive to the antibody-drug conjugate sacituzumab govitecan

E. Ratner, D. Silasi, M. Azodi, 2019, Scientific Reports.

Polymerase ε (POLE) ultra-mutation in uterine tumors correlates with T lymphocyte infiltration and increased resistance to platinum-based chemotherapy in vitro.

E. Sartori, E. Ratner, D. Silasi, 2017, Gynecologic oncology.

Mechanisms of resistance to HER2-targeted therapies in HER2-amplified uterine serous carcinoma, and strategies to overcome it.

P. Schwartz, A. Santin, G. Menderes, 2018, Discovery medicine.

PI3K oncogenic mutations mediate resistance to afatinib in HER2/neu overexpressing gynecological cancers.

Gloria S. Huang, E. Ratner, D. Silasi, 2019, Gynecologic oncology.

Inhibition of BET Bromodomain Proteins with GS-5829 and GS-626510 in Uterine Serous Carcinoma, a Biologically Aggressive Variant of Endometrial Cancer

Gloria S. Huang, J. Schlessinger, E. Ratner, 2018, Clinical Cancer Research.

Dual-Targeting Nanoparticles for In Vivo Delivery of Suicide Genes to Chemotherapy-Resistant Ovarian Cancer Cells

E. Ratner, W. Saltzman, D. Silasi, 2016, Molecular Cancer Therapeutics.

Clostridium Perfringens Enterotoxin (CPE) and CPE-Binding Domain (c-CPE) for the Detection and Treatment of Gynecologic Cancers

E. Cocco, A. Santin, J. Black, 2015, Toxins.

Efficacy of neratinib in the treatment of HER2/neu-amplified epithelial ovarian carcinoma in vitro and in vivo

E. Ratner, D. Silasi, P. Schwartz, 2017, Medical Oncology.

Clostridium perfringens enterotoxin C‐terminal domain labeled to fluorescent dyes for in vivo visualization of micrometastatic chemotherapy‐resistant ovarian cancer

C. Zeiss, E. Ratner, W. Saltzman, 2015, International journal of cancer.

Solitomab, an EpCAM/CD3 bispecific antibody construct (BiTE), is highly active against primary uterine serous papillary carcinoma cell lines in vitro.

E. Ratner, D. Silasi, P. Schwartz, 2016, American journal of obstetrics and gynecology.

Solitomab, an EpCAM/CD3 bispecific antibody construct (BiTE®), is highly active against primary uterine and ovarian carcinosarcoma cell lines in vitro

E. Ratner, D. Silasi, P. Schwartz, 2015, Journal of experimental & clinical cancer research : CR.

PIK3CA oncogenic mutations represent a major mechanism of resistance to trastuzumab in HER2/neu overexpressing uterine serous carcinomas

E. Ratner, D. Silasi, M. Azodi, 2015, British Journal of Cancer.

Solitomab, an EpCAM/CD3 bispecific antibody construct (BiTE®), is highly active against primary uterine and ovarian carcinosarcoma cell lines in vitro

E. Ratner, D. Silasi, P. Schwartz, 2015, Journal of experimental & clinical cancer research : CR.

E. Ratner, D. Silasi, T. Rutherford, 2015, Cancer.

Integrated mutational landscape analysis of poorly differentiated high-grade neuroendocrine carcinoma of the uterine cervix.

E. Ratner, M. Azodi, B. Paolini, 2024, Proceedings of the National Academy of Sciences of the United States of America.